|
1kits(10Fiyɛliw) .
| Hakɛ: | |
|---|---|
▎ GLP-3 sigicogo
Sɔrɔyɔrɔ: PubChem |
A kɛcogo: YA⊃1;QGTFTSDYSI-L⊃2;LDKK4AQA⊃1;AFIEYLLEGGPSSGAPPPS⊃3; Formula molekilɛri: C 221H 342N 46O68 Molecules girinya: 4731 g/mol CAS nimɔrɔ: 2381089-83-2 PubChem ka CID: 171390338. Bamako, Mali Kɔrɔɲɔgɔnmaw:LY3437943 |
▎ GLP-3 Sɛgɛsɛgɛli
GLP-3 ka ɲininiw kɛcogo ye mun ye?
GLP-3 ka ɲininiw kɔkankow bɛ tali kɛ kosɛbɛ diɲɛ kɔnɔ ko juguw la minnu bɛ ka caya ka taa a fɛ, n’o ye fasa ni farikoloɲɛnajɛ ye, ani fana furakɛli fura minnu bɛ yen, olu dan ye: fasa ni farikoloɲɛnajɛ bɛ faratiba lase foroba kɛnɛya ma, ni diɲɛ kɔnɔ fasa hakɛ bɛ se miliyari 4,005 ma san 2035 kɔnɔ, ani farikoloɲɛnajɛ banabagatɔw hakɛ bɛna caya ka se miliyɔn 592 ma, min bɛ na ni diɲɛ kɛnɛyako musakabaw ye ka da farikoloɲɛnajɛ kan. Pepitiri agoniste recepteurs multi-targets bɔra kɛnɛ kan i n’a fɔ fura, minnu bɛ se ka fasa bali, ka farikoloɲɛnajɛ furakɛ, ani ka fura kɔrɔw kɔlɔlɔ toxicw bali, o b’a to u bɛ kɛ ŋaniya ye fasa ni farikoloɲɛnajɛ furakɛli yiriwali la.
GLP-3 ka baarakɛcogo ye mun ye?
Fanga sɛnɛcogo labɛnni ni sɔrɔyɔrɔ caman baarakɛcogo ye
GLP-3 ye agoniste saba ye min bɛ tali kɛ glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R) ani glucagon receptor (GCGR) la. A bɛ nin fɛn saba ninnu baara waati kelen na, ka fanga sɛnɛcogo ɲɛnabɔ sira caman fɛ.
GIPR agoniste ka baarakɛcogo:
GIP ye banakɔtaa inisɔndiyalan ye min bɛ bɔ banakɔtaa K selilɛriw fɛ ka bɔ dumuni kɔfɛ. GLP-3 bɛ GIPR baara, ka inisɔndiya bɔli sabati, ka inisɔndiya kɛcogo ɲɛ, o la, a bɛ farikolo dɛmɛ ka sukaro minɛ ka ɲɛ ani ka baara kɛ ni a ye, o la, a bɛ sukaro hakɛ dɔgɔya joli la. Ka fara o kan, GIP bɛ se ka nɔ bila tulumafɛnw falen-falenni na ni a bɛ tulumafɛnw baaracogo ɲɛnabɔ ani ka tulumafɛnw dalajɛli dɔgɔya [1] ..
GLP-1R agoniste ka baarakɛcogo:
GLP-1 ye pepitiri ɔrimɔni ye min bɛ bɔ banakɔtaa L selilɛriw fɛ. GLP-1R baara kɔfɛ, GLP-3 bɛ nafa suguya caman lase. A bɛ se ka inisɔndiya bɔli lawuli cogo la min bɛ bɔ sukaro hakɛ la, o bɛ sukaro hakɛ dɔgɔya joli la. A bɛ se ka kɔnɔbara lankolonya bila kɔfɛ, ka dɔ fara fasa kan, ka dumuni dunta dɔgɔya. GLP-1R agonismu bɛ se ka kɛ fana farikolo cɛmancɛ la, ka dumuni nege ni fanga balansi labɛn, o bɛ dɛmɛ don ka farikolo girinya dɔgɔya [2] ..
GCGR agoniste nɔw:
A ka ca a la, glucagon bɛ dɔ fara joli sukaro hakɛ kan, nka GLP-3 ka fanga kɔrɔ, GCGR agoniste bɛ nɔ wɛrɛw lase mɔgɔ ma. A bɛ glycogenolyse ni gluconeogenesis sabati sugunɛ na. GLP-3 nɔ faralen ɲɔgɔn kan, farikolo tɛ dɔ fara joli sukaro hakɛ kan nɔgɔya la nka o nɔ na, a bɛ fanga sɛnɛcogo ɲɛnabɔ walasa ka tulu tiɲɛni caya, o la, a bɛ se ka girinya dɔgɔya ani ka farikoloɲɛnajɛ kɛcogo ɲɛ. GCGR agoniste fana bɛ se ka nɔ bila sugunɛbilenni na, ka sugunɛ tulumafɛnw dalajɛli dɔgɔya [3] ..
A nɔ minnu bɛ sɔrɔ sukarodunbana fɛ farikoloɲɛnajɛw la
Ni GLP-3 bɛ baara kɛ waati kelen na fɛn saba kofɔlenw kan, a bɛ nɔ bila farikoloɲɛnajɛ kɛcogo caman na minnu bɛ tali kɛ farikoloɲɛnajɛ la.
Joli sukaro hakɛ labɛnni:
Ni GLP-3 ye GIPR ni GLP-1R baara walasa ka insuline bɔli sabati, ani ka GCGR labɛn ka ɲɛ, GLP-3 bɛ se ka joli sukaro hakɛ dɔgɔya. A ka sukarodunbana nɔ bɛ ye ni sukaro hakɛ cayara, ka sɔrɔ a man teli ka sukarodunbana bila mɔgɔ la ni sukaro hakɛ bɛ a la, o min nafa ka bon sukaro hakɛ kunbɛnni na sukarodunbanabagatɔw la.
Kisɛya hakɛ jateminɛ:
GLP-3 bɛ nafa caman jira farikolo girinya kunbɛnni na. Ni a bɛ GLP-1R baara, a bɛ kɔnɔbara lankolonya sumaya, ka dɔ fara fasa kan, ka dumuni dunta dɔgɔya; ni a bɛ tulumafɛnw sɛnɛcogo ɲɛnabɔ, a bɛ tulumafɛnw tiɲɛni ni fanga musaka sabati, o la, a bɛ se ka mɔgɔ girinya dɔgɔya. Kɛnɛyaso sɛgɛsɛgɛliw y’a jira ko banabagatɔ minnu fasalen don walima minnu girinya ka ca ni GLP-3 ye, olu girinya bɛ dɔgɔya kosɛbɛ waati dɔ kɔnɔ [5,6]..
Lipidiw labɛnni:
GLP-3 furakɛli bɛ banabagatɔw ka tulumafɛnw hakɛ ɲɛ. A bɛ triglycérides (TG), kolosinsinnanw (LDL-C), ani kolosinsinnan minnu ka dɔgɔn kosɛbɛ (VLDL-C) hakɛ dɔgɔya, ka sɔrɔ fana ka apolipoprotéines (apolipoprotéines) hakɛw labɛn, i n’a fɔ apolipoprotéine B (apoB) ni apolipoprotéine C -III (apoC-III) hakɛ dɔgɔyali, o la, a bɛ lipoprotéines particules (lipoprotéines) hakɛ dɔgɔya minnu bɛ tali kɛ ɲɔgɔn na ni joli siraw sɔgɔsɔgɔli ye ani ka dusukun ni jolisiraw kɛnɛya sabati [7] ..
Sugunɛbilenni farikolojɔli ɲɛnabɔli:
Banabagatɔ minnu ka sugunɛbilenni min tɛ dɔlɔ ye (NAFLD) min bɛ tali kɛ farikoloɲɛnajɛ baarakɛbaliya la, GLP-3 bɛ sugunɛ tuluma hakɛ dɔgɔya kosɛbɛ. Kɛnɛyaso sɛgɛsɛgɛliw la minnu bɛ tali kɛ o ko la, banabagatɔ minnu furakɛra ni GLP-3 hakɛ danfaralenw ye, olu ye dɔ bɔ sugunɛ tulu hakɛ la kosɛbɛ ni i y’a suma ni a daminɛ na, o b’a jira ko GLP-3 bɛ nɔ ɲuman bila sugunɛ tulu sɛnɛcogo la, o min nafa ka bon sugunɛ baarakɛcogo ɲɛ.
Jaa 1 GLP-3 ka baarakɛcogo [8] ..
GLP-3 baarakɛcogo ye mun ye?
Fasa furakɛli:
Fasa kɛra diɲɛ foroba kɛnɛyako gɛlɛnba ye, min ni bana basigilen suguya caman daminɛni n’u taabolo bɛ tali kɛ ɲɔgɔn na kosɛbɛ. GLP-3 ye nafa caman jira fasa furakɛli la. Banabagatɔ fasalenw minnu furakɛra ni GLP-3 ye, olu farikolo girinya dɔgɔyara kosɛbɛ. Dɔgɔkun 48 kɔnɔ, fasa 2nan sɛgɛsɛgɛli la, banabagatɔ minnu furakɛra ni GLP-3 miligaramu 8 ni miligaramu 12 ye, olu girinya dɔgɔyara ni 22,8% ani 24,2% ye. Fase 2 sɛgɛsɛgɛli wɛrɛ la, min kɛra ni fiyentɔya fila ye, min kɛra ni mɔgɔw ye, min kɛra ni furakisɛ ye, banabagatɔ minnu tun bɛ fura tata hakɛ danfaralenw na, olu girinya hakɛ tɛ kelen ye dɔgɔkun 24 ni dɔgɔkun 48 kɔnɔ. Miligaramu 12 ta kulu ye 24,2% dɔgɔya dɔgɔkun 48 kɔnɔ, ka sɔrɔ furakisɛ ta kulu ye -2,1% dɔrɔn dɔgɔya. GLP-3 bɛ farikolo girinya dɔgɔya kosɛbɛ banabagatɔ fasalenw na, o bɛ kɛ baarakɛminɛn kura ni barikama ye fasa furakɛli la. GLP-3 furakɛli min bɛ kɛ fasa la, o tɛ farikolo girinya dɔgɔya dɔrɔn, nka a bɛ se ka kɛnɛyako wɛrɛw fana ɲɛ ka taa a fɛ, minnu bɛ tali kɛ fasa la, i n’a fɔ ka kolotugudaw degunw nɔgɔya ani ka kolotugudaw bana taamasiɲɛw nɔgɔya farikolojidɛsɛ fɛ girinya dɔgɔyali fana bɛ se ka dɛmɛ don ka fasa gɛlɛyaw ɲɛnabɔ i n’a fɔ sunɔgɔbaliya [3,6]..
Farikoloɲɛnajɛ suguya 2 furakɛli:
Farikoloɲɛnajɛ suguya 2 ye farikoloɲɛnajɛ basigilen ye min ka teli ka sɔrɔ, a bɛ sɔrɔ inisɔndiya tali fɛ ani inisɔndiya bɔli dafalen na. GLP-3 nafa bɛ se ka kɛ farikoloɲɛnajɛ suguya 2 furakɛli la. A bɛ inisɔndiya bɔli lawuli ni a bɛ GLP-1 minɛbaga baara, ka inisɔndiya kunbɛncogo ɲɛ, ani ka joli sukaro hakɛ dɔgɔya. A ka girinya dɔgɔyali nɔ fana bɛ dɛmɛ ka farikoloɲɛnajɛ suguya 2 banabagatɔw ka cogoya ɲɛ, barisa fasa ye faratiba ye farikoloɲɛnajɛ suguya 2 la, wa farikolo girinya dɔgɔyali bɛ se ka inisɔndiya sabati, o bɛ dɛmɛ wɛrɛ don joli sukaro kɔlɔsili la. Kalan minnu kɛra banabagatɔw kan minnu ka farikoloɲɛnajɛ suguya 2 bɛ u la, GLP-3 kɛra sababu ye ka farikolo girinya dɔgɔya kosɛbɛ ani ka dɔ bɔ kosɛbɛ ɛmoɲini A1c (HbA1c) hakɛ la, ni HbA1c dɔgɔyara ni 1,64% ye ni i ye a suma ni furakisɛ ta ye. O b’a jira ko GLP-3 tɛ joli sukaro hakɛ dɔrɔn kɔlɔsi ka ɲɛ, nka a bɛ banabagatɔw ka farikoloɲɛnajɛ suguya filanan fana ka cogoya bɛɛ ɲɛ ka tɛmɛ fɛɛrɛ caman fɛ, farikolo girinya dɔgɔyali fana sen bɛ o la, o la, a bɛ u ka ɲɛnamaya kɛcogo ɲɛ.
Sugunɛbilenni min tɛ dɔlɔ ye (NAFLD) furakɛli:
NAFLD ye sugunɛ jogin ye min bɛ sɔrɔ farikoloɲɛnajɛ degun fɛ, a ni inisɔn tali ni jamu tali bɛ tali kɛ ɲɔgɔn na kosɛbɛ, a bɛ bana caman lajɛ i n’a fɔ sugunɛbilenni nɔgɔman min tɛ dɔlɔ ye, sugunɛbilenni min tɛ dɔlɔ ye, ani sirozi min bɛ tali kɛ o la. GLP-3 bɛ se ka layidu ta NAFLD furakɛli la. Kɔrɔbɔli dɔ la, min kɛra ni mɔgɔ fila ye, min kɛra ni furakisɛ ye, min kɛra ni mɔgɔ minnu ye, ni sugunɛbilenni min bɛ tali kɛ farikoloɲɛnajɛ baarakɛbaliya la, ani sugunɛ tuluma hakɛ ≥10%, dɔgɔkun 24 kɔnɔ, sugunɛ tulu hakɛ caman yeli hakɛ danmadɔ ka bɔ a daminɛ na, o tun tɛ kelen ye kosɛbɛ GLP-3 tata hakɛ kuluw bɛɛ la: -81,4% miligaramu 8 kulu la, -82,4% miligaramu 12 kulu la, ani +0,3% furakisɛ tali kulu la. O b’a jira ko GLP-3 bɛ se ka sugunɛ tulu hakɛ dɔgɔya kosɛbɛ, o min nafa ka bon kosɛbɛ NAFLD banabagatɔw ka sugunɛbana furakɛli la. A bɛ layidu ta i n’a fɔ furakɛlicogo kura NAFLD la, min bɛ se ka bana taabolo sumaya ani ka gɛlɛya jugumanw farati dɔgɔya i n’a fɔ sirozi [3] ..
Kuncɛli
GLP-3 bɛ seko ɲuman jira NAFLD banabagatɔw ka sugunɛbana cogoya ɲɛnabɔli la, a bɛ baara kɛ ni fɛɛrɛ caman ye i n’a fɔ fanga sɛnɛcogo ɲɛnabɔli, inisɔndiya kunbɛncogo ɲɛnabɔli, funu kɛlɛli nɔw, ani tulumafɛnw sɛnɛcogo caman sɛgɛsɛgɛli.
A sɛbɛnbaga ko la
Fɛn minnu kofɔlen dòn san fɛ, olu bɛɛ ɲinini Kɛra, k’u Labɛn ani k’u Lajɛ Cocer Peptides fɛ.
Dɔnniya gafe sɛbɛnbaga
Rosenstock, J ye dɔnnikɛla ŋana ye min ka baara bɛ tali kɛ kosɛbɛ baarada tɔgɔba caman na, i n’a fɔ Texas Iniwɛrisite Saheli-Tilebin-yanfan dɔgɔtɔrɔso, Texas Iniwɛrisite Dallas, ani Kanada VIGOR Centre. A ka ɲininiw bɛ dakun caman na i n’a fɔ Endocrinology & Diabetes, General & Internal Medicine, Cardiovascular System & Cardiology, Pharmacology & Pharmacy, ani Research & Experimental Medicine. A ka dɛmɛ kabakoma minnu kɛra kalanko jɛkulu kɔnɔ, o y’a to a ye bonya sɔrɔ kosɛbɛ, i n’a fɔ a jiralen bɛ cogo min na a ka sugandili segin-segin fɛ ka kɛ 'Sɛgɛsɛgɛlikɛla min tɔgɔ fɔra kosɛbɛ kɛnɛyako furakɛli siratigɛ la' k’a ta san 2017 la ka se san 2024 ma, o y’a jira k’a jɔyɔrɔba n’a nɔba bɛ kɛnɛyako ɲininiw na. Rosenstock J tɔgɔ sɛbɛnnen bɛ citation (citation) ɲɛfɔli sɛbɛn kɔnɔ [4].
